Patient Case Studies
Patient Case Studies
KEYTRUDA® (pembrolizumab) Prescribing Information [External link]
LENVATINIB Eisai Prescribing information [External link]
LENVATINIB Eisai will be referred to as LENVATINIB across this page.
KEYTRUDA, in combination with LENVATINIB, is indicated for the first-line treatment of advanced renal cell carcinoma in adults.1
Welcome to the advanced RCC (aRCC) KEYLearning Hub – hear how UK Oncologists approach complex first-line aRCC cases and share their experiences of managing patients treated with KEYTRUDA in combination with LENVATINIB.
CPD Certified eLearning Module – Interactive Patient Case Studies
Complete the enhanced eLearning module to deepen your understanding of 1L aRCC management through four real‑world patient case studies.
This upgraded format brings together expert insights, clinical resources and reflective learning tools in one seamless experience—designed to support you in applying learning directly to clinical practice. Please note, we recommend completing this eLearning module on desktop computer or laptop.
Prefer to review the content in its original format or view on your mobile?
Watch the four individual case study videos as stand‑alone clips in the tab above ‘Case study videos’. This is ideal for quick refreshers or focused deep‑dives into specific patient scenarios.
Please refer to the individual product SmPCs before prescribing.
Patient case studies eLearning module
What’s included
- Four patient case studies featuring Dr Ricky Frazer, Dr John McGrane, Dr Richard Griffiths and Dr Balaji Venugopal
- Self‑reflection questions to consolidate learnings and support real‑world application
Estimated time to complete
Approx. 40-80 minutes depending on pace.
Learning experience
- CPD‑certified module with certificate available upon completion
- Automatically saved progress so you can return anytime
- Flexible navigation across case studies and reflection questions
- Improved usability with cleaner layout and simplified certificate download process
Dr Ricky Frazer
Consultant Medical Oncologist
Velindre Cancer Centre, Cardiff
Dr John McGrane
Consultant Clinical Oncologist
Royal Cornwall Hospitals NHS Trust, Truro
Dr Richard Griffiths
Consultant Medical Oncologist
The Clatterbridge Cancer Centre NHS Foundation Trust
Dr Balaji Venugopal
Consultant Medical Oncologist and Honorary Clinical Senior Lecturer
Beatson West of Scotland Cancer Centre, Glasgow
Video case studies – watch on demand
Prefer to review the content in its original format?
Watch the four individual case study videos as stand‑alone clips. This is ideal for quick refreshers or focused deep‑dives into specific patient scenarios.
What you can do here
- Watch each case study video individually to revisit key decision points, treatment rationales and clinical considerations
- Use videos for quick refreshers ahead of clinics, MDTs or discussions with colleagues
- Access supporting resources such as dosing guidance, AE management tools and clinical data
Patient case studies in first-line advanced RCC
Optimise treatment outcome for your 1L aRCC patients treated with KEYTRUDA® (pembrolizumab) plus LENVATINIB Eisai
Please refer to the individual product SmPCs before prescribing.
How to select first-line treatment for advanced RCC patient present with multiple metastases
Case study summary
Dr Ricky Frazer, describes his treatment decision making, management of adverse events and the patient’s treatment outcome.
Dr Ricky Frazer, Consultant Medical Oncologist at the Velindre Cancer Centre in Cardiff presents a case study of a 57 year old male with advanced renal cell carcinoma, treated with KEYTRUDA in combination with LENVATINIB. This patient was diagnosed with multiple metastases (lung mets and large bone mets) and was classified as IMDC intermediate risk.
KEYTRUDA® (pembrolizumab) Prescribing Information [External link]
LENVATINIB Prescribing information [External link]
Filmed: May 2023 | Length: 10:31
Symptomatic intermediate risk patient presented with Sarcomatoid features and bone metastases
Case study summary
Dr John McGrane, Consultant Clinical Oncologist at the Royal Cornwall Hospitals NHS Trust in Truro presents a case study of a 62 year old male with advanced renal cell carcinoma, treated with KEYTRUDA in combination with LENVATINIB. This patient was diagnosed with sarcomatoid features and bone metastases and was classified as IMDC intermediate risk.
Dr John McGrane, describes his treatment decision making, management of adverse events and the patient’s treatment outcome.
KEYTRUDA® (pembrolizumab) Prescribing Information [External link]
LENVATINIB Prescribing information [External link]
Filmed: June 2023 | Length: 11:22
Asymptomatic Intermediate risk patient presented with spinal metastases, pulmonary and adrenal nodules
Case study summary
Dr Richard Griffiths, Consultant Medical Oncologist at the Clatterbridge Cancer Centre NHS Foundation Trust presents a case study of a 61 year old female with advanced renal cell carcinoma, treated with KEYTRUDA in combination with LENVATINIB. This patient was diagnosed with spinal metastases, pulmonary and adrenal nodules and was classified as IMDC intermediate risk.
Dr Richard Griffiths, describes his treatment decision making, management of adverse events and the patient’s treatment outcome.
KEYTRUDA® (pembrolizumab) Prescribing Information [External link]
LENVATINIB Prescribing information [External link]
Filmed: June 2023 | Length: 09:23
AE management focus on hypertension
Case study summary
Dr Balaji Venugopal, Consultant Medical Oncologist at Beatson Cancer Centre in Glasgow, presents a case study of a 68-year-old male with advanced renal cell carcinoma, treated with KEYTRUDA in combination with LENVATINIB. This patient was diagnosed with pulmonary and adrenal nodules and was classified as IMDC intermediate risk.
Dr Balaji Venugopal, describes his treatment decision and patient’s outcomes, focusing on how to manage the adverse events that emerged during the treatment, with special focus on hypertension management.
KEYTRUDA® (pembrolizumab) Prescribing Information [External link]
LENVATINIB Prescribing information [External link]
Filmed: March 2024 | Length: 08:52
Complete the full eLearning module to gain CPD accreditation here
Want to hear directly from your peer Oncologists?
Explore our medical education offering to bring experienced Oncologists to speak to you & your MDT locally at your trust.
Expert on Demand in First-line Advanced Renal Cell Carcinoma (RCC)
The Expert on Demand educational programme is promotional and is organised and fully funded by MSD. For UK healthcare professionals only. MSD and Eisai products will be mentioned within the Expert on Demand programme.
Further resources
Reference
1. KEYTRUDA Summary of Product Characteristics.
Supporting documentation
KEYTRUDA Prescribing Information
LENVATINIB Prescribing information
By clicking the links above you will leave the MSD Connect website and be taken to an external website
